Last reviewed · How we verify
NCT05123677: COMPaRE
Cardiac Output Monitoring to Predict Pre-Eclampsia and Restricted Growth (COMPaRE)
trial testing Non-invasive haemodynamic assessment in Fetal Growth Retardation in 200 participants. Status unknown.
1 June 2023
Quick facts
| Lead sponsor | Sandwell & West Birmingham Hospitals NHS Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2023 |
| Estimated completion | 1 August 2023 |
Drugs / interventions tested
- Non-invasive haemodynamic assessment
- Maternal ophthalmic artery doppler
Conditions studied
- Fetal Growth Retardation — all drugs for Fetal Growth Retardation →
- Pre-Eclampsia — all drugs for Pre-Eclampsia →
Sponsor
Sandwell & West Birmingham Hospitals NHS Trust
Who can join
18 and older, female only, with Fetal Growth Retardation or Pre-Eclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pre-eclampsia (PET) and fetal growth restriction (FGR) are common complications of pregnancy that affect up to 15% of pregnancies in the UK. These conditions can have potentially devastating consequences to mothers and babies in pregnancy. Pre-term birth, that is often medically indicated to treat severe PET and FGR can cause cerebral palsy, breathing difficulty, developmental delay and even death in affected babies. Mothers who suffer from PET are at risk of seizures, strokes, multi-organ failure and future chronic hypertension. It is now thought that PET and FGR may result from poor adaptation of the maternal cardiovascular system to normal pregnancy. This project aims to study the patterns within the maternal cardiovascular system and haemodynamic profile in women who are at high risk of PET and FGR by using non-invasive methods to gather information about the functions of their hearts and major blood vessels. The investigators hope to elucidate the patterns that may offer an early warning to mothers who may develop PET and whose fetuses may be growth restricted. This would be an opportunity to more closely monitor, modify risk factors and treat earlier women who develop these conditions. Women who are at a high risk of PET and FGR as stipulated in the relevant Royal College of Obstetrics \& Gynaecology and National Institute of Clinical Excellence guidelines and who give their consent will be eligible for the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05123677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fetal Growth Retardation
Currently open trials in the same condition.
- NCT06952777 — Validation of Sensors for Long-term Non-Invasive Fetal Monitoring · NA · recruiting
- NCT06405360 — DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development · NA · active not recruiting
- NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
- NCT06215690 — Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction · active not recruiting
- NCT06416995 — Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes · recruiting
Other Sandwell & West Birmingham Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT06790836 — Correlation of FFR CT With Invasive FFR in Multi-ethnic Cohort- a Retrospective Study · not yet recruiting
- NCT06765785 — Cardiovascular Screening in Asymptomatic South Asians · NA · not yet recruiting
- NCT06414551 — Calcification on CTCA of a CTO and PCI Outcomes · recruiting
- NCT06305169 — Measuring the Negative Predictive Value and Specificity of Serum Biomarkers in Gastric Cancer · unknown
- NCT05845463 — The Impact of Artificial Intelligence (AI) on the Quality of Upper Gastrointestinal (GI) Endoscopy · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05123677 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sandwell & West Birmingham Hospitals NHS Trust
- Last refreshed: 17 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05123677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing